The urban training intervention increases physical activity in COPD patients

(Barcelona Institute for Global Health (ISGlobal)) Increasing physical activity in patients with chronic obstructive pulmonary disease (COPD) is a key strategy -- and a major challenge -- in the fight against this respiratory disorder. According to a study published in European Respiratory Journal, the Urban Training intervention for COPD patients designed by the Barcelona Institute for Global Health (ISGlobal) -- an institution supported by 'la Caixa' Foundation -- has proved efficacious in achieving, for the first time, a significant long-term increase in physical activity.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news

Related Links:

Publication date: Available online 17 May 2019Source: Journal of Molecular Graphics and ModellingAuthor(s): S. Dharani, V. Nagarajan, R. ChandiramouliAbstractWe systematically investigated the adsorption characteristics of chronic obstructive pulmonary disease (COPD) biomarker volatiles on violet phosphorene with density functional theory approach. The formation energy of violet phosphorene indicates its stable structure. The electronic properties of violet phosphorene credit that it is a suitable material for biosensors. We explored the adsorption mechanism of hexanal and nonanal molecules based on electron density variat...
Source: Journal of Molecular Graphics and Modelling - Category: Molecular Biology Source Type: research
Publication date: Available online 17 May 2019Source: Revista Clínica Española (English Edition)Author(s): R. Boixeda, J. Díez-Manglano, M. Gómez-Antúnez, F. López-García, J. Recio, P. AlmagroAbstractThe comorbidity, obstruction, dyspnea, exacerbations (CODEX) index is the first multicomponent scale designed to predict the risk of readmissions and mortality at 1 year for patients hospitalised for chronic obstructive pulmonary disease (COPD). The index includes the comorbidities (C) (measured by the Charlson index), the degree of obstruction (O) (assessed by the forced expira...
Source: Revista Clinica Espanola - Category: Internal Medicine Source Type: research
Source: International Journal of Tuberculosis and Lung Disease - Category: Respiratory Medicine Authors: Tags: EDITORIALS Source Type: research
Conclusion: The ProGRP value is the only indicator that distinguishes the PNET group from the other 3 groups. PMID: 31091854 [PubMed - as supplied by publisher]
Source: Turkish Journal of Medical Sciences - Category: General Medicine Tags: Turk J Med Sci Source Type: research
Authors: Hu WP, Lhamo T, Liu D, Hang JQ, Zhang FY, Zuo YH, Zeng YY, Zhang J Abstract Acute exacerbation (AE) is the main cause of increased disability and mortality for patients with Chronic Obstructive Pulmonary Disease (COPD). Short-term re-exacerbation after discharge is common for in-hospital patients with AECOPD. Thus, we aimed to design a scoring system to effectively predict the 30-day re-exacerbation using simple and easily accessible variables. We retrospectively enrolled 686 cases hospitalized for AECOPD in two Chinese hospitals from 2005 to 2017. A variety of parameters were collected like demographics, ...
Source: COPD: Journal of Chronic Obstructive Pulmonary Disease - Category: Respiratory Medicine Tags: COPD Source Type: research
Authors: Neder JA, Marillier M, Bernard AC, James MD, Milne KM, O'Donnell DE Abstract Supervised exercise training (EXT) as part of pulmonary rehabilitation is arguably the most effective intervention for improving exercise tolerance in patients with chronic obstructive pulmonary disease (COPD). In the current review, we focus on the physiological rationale for EXT and the expected physiological benefits that can be achieved in patients who can be exposed to sufficiently high training stimuli. Thus, after a brief consideration of the mechanisms of exercise limitation and their sensory consequences, we expose the po...
Source: COPD: Journal of Chronic Obstructive Pulmonary Disease - Category: Respiratory Medicine Tags: COPD Source Type: research
Airway remodelling in chronic obstructive pulmonary disease (COPD) originates, in part, from smoking-induced changes in airway basal stem/progenitor cells (BCs). Based on the knowledge that bone morphogenetic protein 4 (BMP4) influences epithelial progenitor function in the developing and adult mouse lung, we hypothesised that BMP4 signalling may regulate the biology of adult human airway BCs relevant to COPD. BMP4 signalling components in human airway epithelium were analysed at the mRNA and protein levels, and the differentiation of BCs was assessed using the BC expansion and air–liquid interface models in the abse...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Original Articles: Basic science Source Type: research
This article explains the evidence and rationale for the GOLD 2019 pharmacological treatment recommendations.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Reviews Source Type: research
In chronic obstructive pulmonary disease (COPD), exacerbation history is the strongest predictor of future exacerbation risk [1, 2]. Large cohort studies have shown that patients with one exacerbation in the previous year have an approximately two-fold increased future exacerbation risk compared to patients with no exacerbations, the risk increasing to five-fold in those with two or more exacerbations [1, 2]. Most clinical trials of pharmacological treatments designed to prevent exacerbations have therefore used the inclusion criterion of at least one exacerbation in the previous year, with a minority requiring at least tw...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Original Articles: Research letters Source Type: research
Condition:   Pulmonary Disease, Chronic Obstructive Interventions:   Drug: Long-acting muscarinic antagonist+ Long-acting beta2 adrenoceptor agonist;   Drug: Tripple combination of Free or fixed Long-acting muscarinic antagonist+ Long-acting beta2 adrenoceptor agonist Sponsor:   Boehringer Ingelheim Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Chronic Obstructive Pulmonary | Respiratory Medicine | Study | Training | Universities & Medical Training